Text Size
Trial record 2 of 352 for:    Open Studies | "Myeloproliferative Disorders"
Previous Study | Return to List | Next Study

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Stanford University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT01144780
First received: June 14, 2010
Last updated: August 9, 2010
Last verified: August 2010
History of Changes
  Purpose

The objective of this study is to better understand the underlying pathogenetic mechanisms of MPDs. We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.


Condition
Myeloproliferative Disorders
Myeloproliferative Disorders (MPD)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA

blood and bone marrow


Estimated Enrollment: 20
Study Start Date: September 2009
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).

Criteria

Inclusion Criteria:Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).

Exclusion Criteria:Any patient who is not willing to give consent.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01144780

Contacts
Contact: Stephen Oh (650) 723-7875 stoh@stanford.edu

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Stephen Oh     650-723-7875     stoh@stanford.edu    
Contact: Cancer Clinical Trials Office     (650) 498-7061        
Principal Investigator: Jason Robert Gotlib            
Principal Investigator: Stephen Tracy Oh            
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Jason Robert Gotlib Stanford University
Principal Investigator: Stephen Tracy Oh Stanford University
  More Information

No publications provided

Responsible Party: Jason Robert Gotlib, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT01144780     History of Changes
Other Study ID Numbers: SU-07092009-3060, HEMMPD0011
Study First Received: June 14, 2010
Last Updated: August 9, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases

ClinicalTrials.gov processed this record on May 23, 2013